Provided by Tiger Trade Technology Pte. Ltd.

BOAN BIOTECH

4.310
+0.0100.23%
Volume:3.70M
Turnover:15.71M
Market Cap:2.68B
PE:27.05
High:4.365
Open:4.300
Low:4.175
Close:4.300
52wk High:16.520
52wk Low:4.110
Shares:622.00M
HK Float Shares:622.33M
Volume Ratio:0.80
T/O Rate:0.59%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.159
ROE:0.33%
ROA:0.59%
PB:0.84
PE(LYR):27.05
PS:2.93

Loading ...

Shandong Boan Biotech shareholders adopt restricted share unit incentive scheme at AGM

Reuters
·
Jun 22

Boan Biotechnology Licenses Diabetes Drug Biosimilar in US

MT Newswires Live
·
Jun 12

BOAN BIOTECH Grants U.S. Rights for BA5101, the First Trulicity® Biosimilar, in Licensing Agreement

Bulletin Express
·
Jun 11

BOAN BIOTECH Secures US Licensing Agreement for Dulaglutide Injection

Stock News
·
Jun 11

BRIEF-Shandong Boan Biotechnology Announces Licensing Of Dulaglutide Injection In US

Reuters
·
Jun 11

Shandong Boan Biotech licenses U.S. rights to dulaglutide biosimilar BA5101 to partner

Reuters
·
Jun 11

Shandong Boan Biotechnology Co Ltd - Licensing of Dulaglutide Injection in U.S.

THOMSON REUTERS
·
Jun 11

Boan Biotech: No Share Capital Changes in May; Public Float Remains Above 18.14% Waiver Threshold

Bulletin Express
·
Jun 03

BOAN BIOTECH Submits US Applications for Two Denosumab Biosimilars

Stock News
·
May 29

Shandong Boan Bio submits US FDA BLA for two denosumab biosimilars

Reuters
·
May 29

Shandong Boan Biotechnology Co Ltd - Bla Submission for Two Denosumab Biosimilars in U.S. to FDA

THOMSON REUTERS
·
May 29

Shandong Boan Biotechnology Co Ltd - Ba6101 Obtained Marketing Approved in Bolivia

THOMSON REUTERS
·
May 29

BOAN BIOTECH Sets 22 June 2026 AGM; Seeks Fresh Share Mandates and Launches 2% RSU Plan

Bulletin Express
·
May 27

BOAN BIOTECH Sets 22 June 2026 AGM; Seeks 20% Share Issuance Mandate, 10% Buy-Back Authority and RSU Scheme Approval

Bulletin Express
·
May 27

Shandong Boan Biotechnology announces annual shareholder meeting

Reuters
·
May 27

Shandong Boan Biotechnology Says Boluojia (Denosumab Injection) Approved By NMPA

Reuters
·
May 26

BOAN BIOTECH's Denosumab Injection BOLUOGA® Gains New Indication Approval in China

Stock News
·
May 26

Shandong Boan says China regulator approves expanded Boluojia use for bone metastases, multiple myeloma

Reuters
·
May 26

Shandong Boan Biotechnology Co Ltd - Boluojia (Denosumab Injection) Approved in China for Bone Metastases by Nmpa

THOMSON REUTERS
·
May 26

Stock Track | BOAN BIOTECH Soars 14.97% Intraday on Share Buyback Plan and Macau Drug Approval

Stock Track
·
May 19